RHY 4.76% 6.0¢ rhythm biosciences limited

Ann: RHY Advances Platform Expansion with Other Cancers, page-5

  1. 1,533 Posts.
    lightbulb Created with Sketch. 145
    Well done Glenn and the team at Rhythm.

    This ann also shows how confident RHY are about their cancer detection technology platform - which gives me more confidence about the upcoming TGA outcome.

    Reading into the ann it appears they are making fairly timely progress identifying lead biomarkers for pan cancer candidates. Phase one complete. Now we get into the interesting phases.

    Very organised and smooth operation.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.